Back to search

Switzerland· 62764002

Selincro, Filmtabletten

A nalmefene product containing nalmefenum, registered in Switzerland by Lundbeck (Schweiz) AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC N07BB05

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedSelincro, FilmtablettenATCN07BB05REGISTER NO.62764002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Nalmefene is registered in 14 of 19 countries.

Countries holding a registration under ATC N07BB05 (nalmefene), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Nalmefene · ATC N07BB05

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nalmefene costs, country by country.

Normalised to the WHO defined daily dose (18 mg), the median price runs from $3.31 in France to $6.33 in Switzerland — a ×1.9 gap.

  • Switzerland: $6.33 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Nalmefene · price per daily dose (18 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$6.33
  • FR France$3.31
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
nalmefenum
Manufacturer
Lundbeck (Schweiz) AG
Country
Switzerland (CH)
ATC code
N07BB05
ATC class
Nalmefene
Defined daily dose
18 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680627640020
    14 Stk
    CHF 81.4

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for nalmefene.

Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nalmefene · interactions on record

5 records

  • 4 moderate
  • 1 minor

Most severe, free to view

  • Methylnaltrexone bromideA06AH01moderate
  • NaloxegolA06AH03moderate
  • NaldemedineA06AH05moderate
  • GlimepirideA10BB12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nalmefene in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nalmefene products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Germany · Nalfino
  • France · Nalmefene Biogaran
  • Iceland · Selincro
  • Norway · Selincro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/39e018c4-ea1a-4981-a9d7-3ee0bb0809c3
GET /v1/drugs/39e018c4-ea1a-4981-a9d7-3ee0bb0809c3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "nalmefenum 18 mg",
  "valid_from": "2014-11-01",
  "limitations": "[{\"description\":\"Zur Reduktion des Alkoholkonsums bei erwachsenen Patienten mit Alkoholabhängigkeit, deren Alkoholkonsum sich auf einem hohen Risiko-Niveau gemäss WHO Drinking Risk Levels (DRLs) für Alkoholkonsum befindet (Alkoholkonsum >60 g/Tag für Männer und >40 g/Tag für Frauen an einem Heavy Drinking Day), bei denen keine körperlichen Entzugserscheinungen vorliegen, und für die keine sofortige Entgiftung erforderlich ist.<br>\\nDie Diagnose der Alkoholabhängigkeit, die Verschreibung, Überwachung und Dokumentation der Therapie muss durch einen geeignet qualifizierten Arzt mit Erfahrung in der Therapie von Alkoholabhängigen erfolgen.<br>\\nDie Behandlung darf nur bei Patienten eingeleitet werden, deren Alkoholkonsum sich 2 Wochen nach einer initialen Untersuchung weiterhin auf einem hohen Risiko-Niveau befindet.<br>\\nNur als zusätzliche Behandlung in Verbindung mit kontinuierlicher psychosozialer Unterstützung, die auf Therapieadhärenz und eine Reduktion des Alkoholkonsums zielt.<br>\\nDie Vergütung erfolgt über einen Zeitraum von maximal 12 Monaten. Eine Vergütung >12 Monate ist nur nach Kostengutsprache nach Evaluation des Behandlungserfolgs und des weiteren Behandlungsbedarfs durch den Vertrauensarzt vorgesehen.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2014-11-01\"}]",
  "galenic_form": "Filmtabl 18 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2014-11-01",
  "self_retention_pct": 10
}

See everything about nalmefene.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.